Vertex Pharmaceuticals (NASDAQ:VRTX) was downgraded by analysts at Cowen from an “outperform” rating to a “neutral” rating in a research report issued to clients and investors on Friday.
Separately, analysts at Goldman Sachs (NYSE: GS) downgraded shares of Vertex Pharmaceuticals from a “buy” rating to a “neutral” rating in a research note to investors on Friday. Analysts at Barclays Capital (NYSE: BCS) raised their price target on shares of Vertex Pharmaceuticals from $38.00 to $44.00 in a research note to investors on Wednesday. They now have an “overweight” rating on the stock. Also, analysts at Credit Suisse (NYSE: CS) raised their EPS on shares of Vertex Pharmaceuticals in a research note to investors on Wednesday. They now have an “outperform” rating and a $42.00 price target on the stock.
Vertex Pharmaceuticals opened at 38.38 on Friday. Vertex Pharmaceuticals has a 52-week low of $26.50 and a 52-week high of $58.87. The stock has a 50-day moving average of $34.86 and a 200-day moving average of $39.77. The company’s market cap is $8.005 billion.
Vertex Pharmaceuticals (NASDAQ:VRTX) resistance level is $42 and support level is $34.
Separately, analysts at Goldman Sachs (NYSE: GS) downgraded shares of Vertex Pharmaceuticals from a “buy” rating to a “neutral” rating in a research note to investors on Friday. Analysts at Barclays Capital (NYSE: BCS) raised their price target on shares of Vertex Pharmaceuticals from $38.00 to $44.00 in a research note to investors on Wednesday. They now have an “overweight” rating on the stock. Also, analysts at Credit Suisse (NYSE: CS) raised their EPS on shares of Vertex Pharmaceuticals in a research note to investors on Wednesday. They now have an “outperform” rating and a $42.00 price target on the stock.
Vertex Pharmaceuticals opened at 38.38 on Friday. Vertex Pharmaceuticals has a 52-week low of $26.50 and a 52-week high of $58.87. The stock has a 50-day moving average of $34.86 and a 200-day moving average of $39.77. The company’s market cap is $8.005 billion.
Vertex Pharmaceuticals (NASDAQ:VRTX) resistance level is $42 and support level is $34.
More Stocks News
For the latest updates on the stock market, visit,
http://daytradingstock-blog.blogspot.com/
